CN108026098B - 作为ido和tdo抑制剂的杂环化合物 - Google Patents

作为ido和tdo抑制剂的杂环化合物 Download PDF

Info

Publication number
CN108026098B
CN108026098B CN201680033890.3A CN201680033890A CN108026098B CN 108026098 B CN108026098 B CN 108026098B CN 201680033890 A CN201680033890 A CN 201680033890A CN 108026098 B CN108026098 B CN 108026098B
Authority
CN
China
Prior art keywords
compound
cancer
mixture
stirred
ido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680033890.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108026098A (zh
Inventor
张汉承
刘世峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Emtronix Medical Technology Co Ltd
Original Assignee
Hangzhou Emtronix Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Emtronix Medical Technology Co Ltd filed Critical Hangzhou Emtronix Medical Technology Co Ltd
Publication of CN108026098A publication Critical patent/CN108026098A/zh
Application granted granted Critical
Publication of CN108026098B publication Critical patent/CN108026098B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680033890.3A 2015-04-12 2016-04-12 作为ido和tdo抑制剂的杂环化合物 Expired - Fee Related CN108026098B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562146340P 2015-04-12 2015-04-12
US62/146,340 2015-04-12
US201662274292P 2016-01-02 2016-01-02
US62/274,292 2016-01-02
PCT/CN2016/079104 WO2016165613A1 (en) 2015-04-12 2016-04-12 Heterocycles useful as ido and tdo inhibitors

Publications (2)

Publication Number Publication Date
CN108026098A CN108026098A (zh) 2018-05-11
CN108026098B true CN108026098B (zh) 2019-09-03

Family

ID=57125732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680033890.3A Expired - Fee Related CN108026098B (zh) 2015-04-12 2016-04-12 作为ido和tdo抑制剂的杂环化合物

Country Status (6)

Country Link
US (1) US10358451B2 (https=)
EP (1) EP3283488A4 (https=)
JP (1) JP2018511647A (https=)
CN (1) CN108026098B (https=)
AU (1) AU2016248366B2 (https=)
WO (1) WO2016165613A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
JP6801159B2 (ja) * 2015-04-21 2020-12-16 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． イミダゾイソインドール誘導体、その製造方法及びその医薬用途
TW201730190A (zh) 2015-12-24 2017-09-01 Genentech Inc Ｔｄｏ２抑制劑
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN107556316B (zh) * 2016-06-30 2021-11-12 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
WO2018028491A1 (zh) * 2016-08-09 2018-02-15 苏州国匡医药科技有限公司 吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN107176956B (zh) * 2017-05-31 2019-11-12 成都海博锐药业有限公司 一种ido抑制剂化合物、药用组合物、用途
US11827639B2 (en) 2017-06-28 2023-11-28 Genentech, Inc. TDO2 and IDO1 inhibitors
EP3645533B1 (en) * 2017-06-28 2025-03-26 Genentech, Inc. Tdo2 and ido1 inhibitors
CN107501272B (zh) * 2017-09-05 2020-03-31 中国药科大学 咪唑并异吲哚类ido1抑制剂、其制备方法及应用
CN108424414A (zh) * 2017-12-08 2018-08-21 苏州国匡医药科技有限公司 一类含杂环的吲哚胺2，3-双加氧酶调节化合物及其在药学中的用途
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
AU2019239952A1 (en) 2018-03-20 2020-10-08 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
EP3810116B1 (en) * 2018-05-31 2023-11-15 Merck Sharp & Dohme LLC Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547579A (zh) * 2011-04-15 2014-01-29 新联基因公司 用作ido抑制剂的稠合咪唑衍生物
WO2016037026A1 (en) * 2014-09-05 2016-03-10 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507255QA (en) 2013-03-14 2015-10-29 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CN105037371A (zh) 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547579A (zh) * 2011-04-15 2014-01-29 新联基因公司 用作ido抑制剂的稠合咪唑衍生物
WO2016037026A1 (en) * 2014-09-05 2016-03-10 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer

Also Published As

Publication number Publication date
EP3283488A4 (en) 2018-10-24
AU2016248366A1 (en) 2017-11-30
US10358451B2 (en) 2019-07-23
CN108026098A (zh) 2018-05-11
AU2016248366B2 (en) 2019-06-13
EP3283488A1 (en) 2018-02-21
WO2016165613A1 (en) 2016-10-20
US20180127418A1 (en) 2018-05-10
JP2018511647A (ja) 2018-04-26

Similar Documents

Publication Publication Date Title
CN108026098B (zh) 作为ido和tdo抑制剂的杂环化合物
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
JP7394074B2 (ja) 治療用化合物
JP6974331B2 (ja) 化合物、組成物及び方法
RU2678990C1 (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
CN109661396B (zh) 作为rock抑制剂的螺稠合环状脲
CN116162099A (zh) 杂环类衍生物及其制备方法和用途
CN112312904A (zh) 螺环化合物
CN116332938A (zh) 稠合三环类衍生物及其制备方法和用途
CN115611898A (zh) 四环类衍生物、其制备方法及其在医药上的应用
CN107709295B (zh) 作为RORγ调节剂的三环砜类
JP2019536785A (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
AU2016360481A1 (en) Novel biphenyl compound or salt thereof
AU2017359023A1 (en) 3-substituted propionic acids as alpha v integrin inhibitors
WO2015077193A1 (en) Inhibitors of lysine methyl transferase
KR20240109977A (ko) Kif18a의 스피로 인돌린 억제제
WO2015077194A1 (en) Inhibitors of lysine methyl transferase
CN112300153A (zh) 一种杂环化合物、药物组合物和用途
CN116113416B (zh) 四环类衍生物、其制备方法和其医药上的用途
EP3967682A1 (en) Bisheterocyclic carbonyl substituted dihydropyrazole compound, preparation method therefor and pharmaceutical use thereof
CN109180681B (zh) 一种dna毒性二聚体化合物
CN115124524A (zh) 三环类衍生物及其制备方法和用途
CN116635028A (zh) c-MYC mRNA翻译调节剂及其在治疗癌症中的用途
EP4141004A1 (en) Polycyclic amide derivative as cdk9 inhibitor, preparation method therefor and use thereof
TW202138352A (zh) 經取代之雙環及三環脲類及醯胺類、其類似物及使用其之方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190903